Overseas partners visited True Health Care (02697) one after another to accelerate the launch of products overseas

The Zhitong Finance App learned that the 2026 Asia-Pacific Economic Cooperation (APEC) Business Leaders Summit will be held in Shenzhen from November 17 to 18. Taking advantage of the APEC Business Leaders Summit, global healthcare industry exchanges continue to heat up. Recently, overseas agents and representatives of medical institutions from Brazil and Germany visited the headquarters of True Health Care (02697) to conduct field visits and in-depth research, explore new paths in the global layout of domestic high-end medical equipment, and establish a solid foundation of cooperation for domestic high-end medical equipment to further explore overseas markets.

Global medical industry collaboration deepens true health care and accelerates layout

China is becoming an important force in global healthcare innovation. In the field of high-end medical equipment, global market development and channel connections are accelerating markedly. According to data from the General Administration of Customs, in the first half of this year, China exported 480 million yuan of surgical robots, an increase of 3.3 times, and the export market expanded from 23 in the same period last year to 49. According to the Frost & Sullivan report, the global surgical robot market is expected to grow from US$32.8 billion in 2026 to US$63.12 billion in 2030. China's surgical robot market size is 22.45 billion yuan in 2026, and is expected to reach 70.85 billion yuan in 2030, with a compound growth rate of 33.3%. Supported by high export growth and domestic market expansion, domestic surgical robots are speeding up import substitution and global layout.

In this context, True Health and Medical have face-to-face exchanges with overseas agents and medical institution representatives from Brazil and Germany on products, entry, and implementation. This is a positive practice of strengthening overseas market connections, deepening products going overseas, and exploring opportunities for cooperation. According to True Health Medical's official account, during the visit, overseas partners closely observed True Health Medical's core products such as puncture surgery robots and microwave ablation surgery robots, and listened to presentations on product technical principles, clinical advantages, application scenarios, and domestic commercialization. Overseas partners highly praised the innovative design, clinical value and localization breakthroughs of the True Health Care series products, and had in-depth exchanges on topics such as overseas clinical entry, localization promotion, and channel implementation, and exchanged opinions on subsequent market cooperation plans.

Overseas registration and market docking parallel multi-product matrices make steady breakthroughs

True Health Medicine already has product advantages in segments such as surgical robots, and is committed to building a modern high-end medical equipment industry system with “puncture surgery robot+ablation surgery robot+full life support system” as the core. Its “domestic first” and “international first” surgical robot products have entered more than 100 medical institutions across the country, and have accelerated replication and application in primary medical institutions, and completed more than 9,000 surgeries. At the end of August this year, it also obtained a sales contract of nearly 100 million yuan for puncture navigation and positioning systems, providing clinical data and operational experience that can be used as a reference for overseas promotion.

At the same time, True Health Care is speeding up the international strategic layout, relying on the advantages of the Hong Kong and Macau internationalization platforms, continuing to connect with high-quality channels and medical institutions in Southeast Asia, Europe and Portuguese-speaking countries, and gradually building overseas support covering registration and clinical training around overseas implementation. According to True Healthcare's official account, CE certification for its core products is expected to be approved within the year, opening up a key entry channel for the European Union and related accreditation system markets; for Portuguese language markets such as Brazil, it is also simultaneously promoting registration of local regulations and preparation of clinical data, and building an overseas commercialization system adapted to regional needs.

In addition to robots for puncture and ablation surgery, real health care has also made phased progress in life support systems. Relying on its self-developed room-temperature organ perfusion system, it successfully completed preclinical trials of 6 cases of gene-edited porcine liver liver-assisted acute liver failure in non-human primate acute liver failure models, setting a record of stable liver function perfusion support treatment for a maximum period of 144 hours and 6 cases exceeding 72 hours. This is the first time in the world that the long-term efficacy of this technology has been verified. The system is a modular organ medical equipment platform and has the technical potential to expand into multi-organ in vitro life support research.

Relying on the innovative advantages of independent research and development, True Health Care is solidly advancing its global strategic layout, building a strong registration and certification network, and deepening collaboration with agents and medical institutions in various countries. The general trend of global healthcare industry cooperation has begun. Domestic medical technology companies represented by True Healthcare will surely follow the trend and advance in depth, bring domestic high-end medical equipment to a wider international stage, and contribute China's strength to the improvement of the global level of minimally invasive medical care.